AzTrials
AzTrials

SchizophreniaPhase 3ZENITHNCT01397786

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

A Phase 3 study testing OPC-34712 in people with Schizophrenia, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 148 sites in 19 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Schizophrenia
What is being tested?
OPC-34712
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,044 participants
Where
148 sitesin 19 countries
Study dates
Sep 2011to Jan 2016
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by DSM-IV-TR criteria
  • Outpatient status at last visit of Trial 331-10-230 or Trial 331-10-231
  • Willing to discontinue all prohibitive psychotropic medications to meet protocol required washouts prior to and during the trial period.
  • Other protocol specific inclusion criteria may apply.

Who cannot join

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug
  • Subjects with a current DSM-IV-TR Axis I diagnosis of:
  • Schizoaffective disorder
  • MDD
  • Bipolar disorder
  • Delirium, dementia, amnestic or other cognitive disorder
Show all 9Show fewer
  • Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder
  • Subjects presenting with a first episode of schizophrenia
  • Other protocol specific exclusion criteria may apply.

Trial locations and contacts

148 sites in 19 countries.

148 sites in 19 countries

United States56 sites
  • Study site

    Allentown, Pennsylvania, 18104

  • Study site

    Anaheim, California, 92805

  • Study site

    Austin, Texas, 78731

  • Study site

    Austin, Texas, 78754

  • Study site

    Birmingham, Alabama, 35226

  • Study site

    Bradenton, Florida, 34208

  • Study site

    Buffalo, New York, 14215

  • Study site

    Cedarhurst, New York, 11516

  • Study site

    Cerritos, California, 90703

  • Study site

    Charleston, South Carolina, 29407

  • Study site

    Chicago, Illinois, 60611

  • Study site

    Dallas, Texas, 75231

  • Study site

    Dallas, Texas, 75243

  • Study site

    Dayton, Ohio, 45417

  • Study site

    Escondido, California, 92025

  • Study site

    Flowood, Mississippi, 39232

  • Study site

    Garden Grove, California, 92845

  • Study site

    Glendale, California, 91206

  • Study site

    Hoffman Estates, Illinois, 60169

  • Study site

    Houston, Texas, 77007

  • Study site

    Jamaica, New York, 11432

  • Study site

    Joliet, Illinois, 60435

  • Study site

    Kirkland, Washington, 98033

  • Study site

    Lake Charles, Louisiana, 70629

  • Study site

    Las Vegas, Nevada, 89102

  • Study site

    Leesburg, Florida, 34748

  • Study site

    Little Rock, Arkansas, 72201

  • Study site

    Little Rock, Arkansas, 72205

  • Study site

    Long Beach, California, 90813

  • Study site

    Maitland, Florida, 32751

  • Study site

    Memphis, Tennessee, 38119

  • Study site

    Miami, Florida, 33143

  • Study site

    Miami Springs, Florida, 33166

  • Study site

    National City, California, 91950

  • Study site

    Norristown, Pennsylvania, 19403

  • Study site

    North Miami, Florida, 33162

  • Study site

    Oak Brook, Illinois, 60523

  • Study site

    Oakland, California, 94612

  • Study site

    Oceanside, California, 92056

  • Study site

    Overland Park, Kansas, 66212

  • Study site

    Pico Rivera, California, 90660

  • Study site

    Richmond, Virginia, 23230

  • Study site

    Rochester, New York, 14618

  • Study site

    Saint Charles, Missouri, 63301

  • Study site

    San Diego, California, 92102

  • Study site

    San Diego, California, 92103

  • Study site

    San Diego, California, 92123

  • Study site

    Shreveport, Louisiana, 71104

  • Study site

    Springdale, Arkansas, 72764

  • Study site

    St Louis, Missouri, 63109

  • Study site

    St Louis, Missouri, 63141

  • Study site

    Staten Island, New York, 10305

  • Study site

    Staten Island, New York, 10312

  • Study site

    Tampa, Florida, 33613

  • Study site

    Torrance, California, 90502

  • Study site

    Washington D.C., District of Columbia, 20016

Other trials in United States

Russia15 sites
  • Study site

    Arkhangelsk, 163530

  • Study site

    Moscow, 117152

  • Study site

    Moscow, 119435

  • Study site

    Moscow Region, 142601

  • Study site

    Nizhny Novgorod, 603155

  • Study site

    Petrozavodsk, 185000

  • Study site

    Saint Petersburg, 190005

  • Study site

    Saint Petersburg, 190121

  • Study site

    Saint Petersburg, 192019

  • Study site

    Saint Petersburg, 194214

  • Study site

    Saint Petersburg, 197341

  • Study site

    Samara, 443016

  • Study site

    Saratov, 410060

  • Study site

    Tomsk, 634014

  • Study site

    Village Nikolskoe, 188357

Other trials in Russia

Ukraine12 sites
  • Study site

    Chernihiv, 14000

  • Study site

    Dnipropetrovsk, 49027

  • Study site

    Dnipropetrovsk, 49115

  • Study site

    Hlevakha, 08631

  • Study site

    Kharkiv, 61068

  • Study site

    Kherson, Vil. Stepanivka, 73488

  • Study site

    Kyiv, 02660

  • Study site

    Kyiv, 04080

  • Study site

    Lviv, 79021

  • Study site

    Odesa, 65014

  • Study site

    Simferopol, 95006

  • Study site

    Vinnytsia, 21005

Other trials in Ukraine

Romania11 sites
  • Study site

    Arad, 310022

  • Study site

    Brasov, 500123

  • Study site

    Bucharest, 010825

  • Study site

    Bucharest, 030442

  • Study site

    Bucharest, 041914

  • Study site

    Cluj-Napoca, 400012

  • Study site

    Craiova, 200473

  • Study site

    Focşani, 620165

  • Study site

    Iași, 700282

  • Study site

    Piteşti, 110069

  • Study site

    Targoviste, 130086

Other trials in Romania

Malaysia6 sites
  • Study site

    Ipoh, 31250

  • Study site

    Jalan Greentown, 30450

  • Study site

    Kajang, Selangor, 43000

  • Study site

    Kota Bharu, Kelantan, 15586

  • Study site

    Kuala Lumpur, Kuala Lumpur, 59100

  • Study site

    Sabak Bernam, 88815

Other trials in Malaysia

Latvia5 sites
  • Study site

    Daugavpils, LV-5417

  • Study site

    Jelgava, LV-3008

  • Study site

    Liepāja, LV-3401

  • Study site

    Riga, LV-1005

  • Study site

    Strenči, LV-4730

Other trials in Latvia

South Korea5 sites
  • Study site

    Incheon, 400-711

  • Study site

    Incheon, 405-760

  • Study site

    Seoul, 136-705

  • Study site

    Seoul, 137-710

  • Study site

    Seoul, 143-711

Other trials in South Korea

Colombia4 sites
  • Study site

    Barranquilla, 00000

  • Study site

    Bello, 00000

  • Study site

    Bogotá, 00000

  • Study site

    Pereira, 00000

Other trials in Colombia

Japan4 sites
  • Study site

    Fujisawa-shi, Kanagawa, 251-8530

  • Study site

    Kumamoto, Kumamoto, 861-8002

  • Study site

    Kunigami-gun, Okinawa, 904-1201

  • Study site

    Sakai-shi, Osaka, 590-0018

Other trials in Japan

Poland4 sites
  • Study site

    Choroszcz, 16-070

  • Study site

    Gdansk, 80-282

  • Study site

    Gdansk, 80-952

  • Study site

    Lodz, 91-229

Other trials in Poland

Serbia4 sites
  • Study site

    Belgrade, 11000

  • Study site

    Kragujevac, 34000

  • Study site

    Novi Kneževac, 23330

  • Study site

    Novi Sad, 21000

Other trials in Serbia

Slovakia4 sites
  • Study site

    Bratislava, 82606

  • Study site

    Michalovce, 07101

  • Study site

    Rimavská Sobota, 97912

  • Study site

    Rožňava, 04801

Other trials in Slovakia

Taiwan4 sites
  • Study site

    Kashsiung, 802

  • Study site

    New Taipei City, 249

  • Study site

    Taipei, 110

  • Study site

    Taoyuan County, 333

Other trials in Taiwan

Mexico3 sites
  • Study site

    Col. Florida, Mexico City, 01030

  • Study site

    Monterrey, Nuevo León, 64060

  • Study site

    San Luis Potosí City, San Luis Potos, 78218

Other trials in Mexico

Philippines3 sites
  • Study site

    Cebu City, 6000

  • Study site

    Davao City, 8000

  • Study site

    Manila, 1000

Other trials in Philippines

Canada2 sites
  • Study site

    Burlington, Ontario, L7R 4E2

  • Study site

    Chatham, Ontario, N7M 5L9

Other trials in Canada

Croatia2 sites
  • Study site

    Rijeka, 51000

  • Study site

    Zagreb, 10090

Other trials in Croatia

Puerto Rico2 sites
  • Study site

    San Juan, 00918

  • Study site

    San Juan, 00927

Other trials in Puerto Rico

Turkey (Türkiye)2 sites
  • Study site

    Diyarbakır, 21280

  • Study site

    Kocaeli, 41380

Other trials in Turkey (Türkiye)

About this study

Official title: A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia.

Read the detailed description

Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.

Conditions
Schizophrenia
Being tested
OPC-34712
Medical subject headings
Schizophrenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OPC-34712Drug

    Phase A: 1-2 mgs/day by mouth, max of 4 wks.

    Phase B: 1-4 mgs/day by mouth, up to 52 weeks

Study groups in NCT01397786
Study groupRoleWhat they receive
OPC-34712ExperimentalNot described
Receives: Drug: OPC-34712

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With Adverse Events (AEs)

    A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption or reduction of IMP.

    Measured: From Baseline up to 52 Weeks

Secondary outcomes (14)
  1. Mean Change From Baseline in Positive and Negative Syndrome Scale Total Score

    The PANSS consisted of 3 subscales with 30 symptom constructs (positive subscale (7): delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/perseckion, and hostility; negative subscale (7): blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and conversation flow, stereotyped thinking and general psychopathology subscale (16): somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). Severity was rated on 7-point scale with scores 1 (absence) \& 7 (extremely severe). The PANSS total score was sum of rating scores for 7 positive, 7 negative, and 16 general psychopathology subscale items of PANSS panel.

    Measured: From Baseline up to 52 Weeks

  2. Mean Change From Baseline in PANSS Positive Subscale Score

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility.

    Measured: From Baseline up to 52 Weeks

  3. Mean Change From Baseline in PANSS Negative Subscale Score

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking.

    Measured: From Baseline up to 52 Weeks

  4. Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale Score

    The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Measured: From Baseline up to 52 Weeks

  5. Mean Change From Baseline in Personal and Social Performance Scale Total Score

    The PSP was a validated clinician-rated scale that measured personal and social functioning in four domains: socially useful activities (e.g, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment that determined the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

    Measured: From Baseline up to 52 Weeks

  6. Mean Clinical Global Impression - Improvement Score

    The efficacy of study medication was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due to the drug treatment. All responses were compared to the participant's condition at Screening/Baseline (i.e, Week 6 visit of Protocol NCT00905307). Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Measured: From Baseline up to 52 Weeks

  7. Response Rate

    Response rate was defined as a reduction of ≥ 30% from Baseline in PANSS total score or CGI-I score of 1 (very much improved) or 2 (much improved) at the Last Visit.

    Measured: From Baseline up to 52 Weeks

  8. Discontinuation Rate for Lack of Efficacy

    Discontinuation rate for the participants who discontinued due to lack of efficacy were examined.

    Measured: From Baseline up to 52 Weeks

  9. Mean Change From Baseline in Positive and Negative Syndrome Scale Excited Component Score

    The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).

    Measured: From Baseline up to 52 Weeks

  10. Mean Change From Baseline in PANSS Marder Factor Scores - Positive Symptoms Score

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score was the sum of the 8 components (delusions (P1), hallucinatory behavior (P3), grandiosity (P5), suspiciousness/persecution (P6), stereotyped thinking (N7), somatic concern (G1), unusual thought content (G9) and lack of judgment and insight (G12)) of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).

    Measured: From Baseline up to 52 Weeks

  11. Mean Change From Baseline in PANSS Marder Factor Scores - Negative Symptoms Score

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items (blunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), lack of spontaneity and conversation flow (N6), motor retardation (G7) and active social avoidance (G16)) of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).

    Measured: From Baseline up to 52 Weeks

  12. Mean Change From Baseline in PANSS Marder Factor Scores - Disorganized Thought Score

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items (conceptual disorganization (P2), difficulty in abstract thinking (N5), mannerisms and posturing (G5), disorientation (G10), poor attention (G11), disturbance of volition (G13) and preoccupation (G15)) on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).

    Measured: From Baseline up to 52 Weeks

  13. Mean Change From Baseline in PANSS Marder Factor Scores - Hostility/ Excitement Score

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items (excitement (P4), hostility (P7), uncooperativeness (G8) and poor impulse control (G14)) on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

    Measured: From Baseline up to 52 Weeks

  14. Mean Change From Baseline in PANSS Marder Factor Scores - Anxiety/Depression Score

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items (anxiety (G2), guilt feelings (G3), tension (G4) and depression (G6)) on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

    Measured: From Baseline up to 52 Weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jul 2011 (estimated)
  2. Study startSep 2011
  3. Primary completionJan 2016
  4. Study completionJan 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
1,044 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01397786
Sponsor's protocol ID
331-10-237
Acronym
ZENITH
Status last verified
Apr 2017
First submitted
11 Jul 2011
Last updated
10 May 2017
Data monitoring committee
No

Publications

  • Citrome L, Farovik A, Palma AM, Yildirim M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia Who Have Hostility and Agitation Symptoms: Post Hoc Analysis of Short- and Long-Term Trials. J Clin Psychiatry. 2026 Jul 20;87(3):26m16448. doi: 10.4088/JCP.26m16448.

    PubMed 42474330
  • Correll CU, He Y, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychiatry. 2022 Mar 1;83(2):20m13793. doi: 10.4088/JCP.20m13793.

    PubMed 35235720
  • Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 May 1;2(1):sgab014. doi: 10.1093/schizbullopen/sgab014. eCollection 2021 Jan.

    PubMed 34901863
  • Newcomer JW, Eriksson H, Zhang P, Weiller E, Weiss C. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. Curr Med Res Opin. 2018 Dec;34(12):2197-2205. doi: 10.1080/03007995.2018.1498779. Epub 2018 Jul 27.

    PubMed 29985680
  • Forbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia. Int J Neuropsychopharmacol. 2018 May 1;21(5):433-441. doi: 10.1093/ijnp/pyy002.

    PubMed 29415258
  • Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Correll CU. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016 Jul;174(1-3):93-98. doi: 10.1016/j.schres.2016.04.013. Epub 2016 May 14.

    PubMed 27188270

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing OPC-34712 in people with Schizophrenia, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 148 sites in 19 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 May 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 148 sites in United States, Russia, Ukraine, Romania, Malaysia and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Mar 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With Adverse Events (AEs) (time frame: From Baseline up to 52 Weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01397786, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in